Tharimmune, Inc. (NASDAQ:THAR) Chairman Purchases $500,000.24 in Stock

Tharimmune, Inc. (NASDAQ:THAR) Chairman Gravitas Capital Lp purchased 337,838 shares of the stock in a transaction on Friday, June 20th. The stock was acquired at an average cost of $1.48 per share, with a total value of $500,000.24. Following the acquisition, the chairman now owns 732,424 shares of the company’s stock, valued at approximately $1,083,987.52. This represents a 85.62% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tharimmune Stock Down 2.2%

Shares of NASDAQ:THAR traded down $0.03 during trading on Monday, hitting $1.31. The stock had a trading volume of 13,761 shares, compared to its average volume of 371,310. Tharimmune, Inc. has a 12-month low of $0.95 and a 12-month high of $6.39. The stock has a market capitalization of $3.48 million, a price-to-earnings ratio of -0.17 and a beta of 1.04. The stock has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $1.64.

Tharimmune (NASDAQ:THAR) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.15).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC acquired a new position in Tharimmune, Inc. (NASDAQ:THAR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned about 1.11% of Tharimmune as of its most recent SEC filing. Institutional investors own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).